1514 related articles for article (PubMed ID: 3123511)
1. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
2. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
[TBL] [Abstract][Full Text] [Related]
3. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
4. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
5. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
7. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
[TBL] [Abstract][Full Text] [Related]
8. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea.
Martin KA; Hall JE; Adams JM; Crowley WF
J Clin Endocrinol Metab; 1993 Jul; 77(1):125-9. PubMed ID: 8325934
[TBL] [Abstract][Full Text] [Related]
9. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.
Couzinet B; Young J; Brailly S; Chanson P; Schaison G
J Clin Endocrinol Metab; 1995 Jul; 80(7):2102-7. PubMed ID: 7608262
[TBL] [Abstract][Full Text] [Related]
10. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
Waldstreicher J; Santoro NF; Hall JE; Filicori M; Crowley WF
J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784
[TBL] [Abstract][Full Text] [Related]
11. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
[TBL] [Abstract][Full Text] [Related]
12. Pulsatile GnRH stimulates normal cyclic ovarian function in amenorrheic lactating postpartum women.
Zinaman MJ; Cartledge T; Tomai T; Tippett P; Merriam GR
J Clin Endocrinol Metab; 1995 Jul; 80(7):2088-93. PubMed ID: 7608260
[TBL] [Abstract][Full Text] [Related]
13. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle.
Nippoldt TB; Reame NE; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1989 Jul; 69(1):67-76. PubMed ID: 2499593
[TBL] [Abstract][Full Text] [Related]
14. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
Rossmanith WG; Wirth U; Benz R; Wolf AS
Gynecol Endocrinol; 1989; 3(1):21-34. PubMed ID: 2658471
[TBL] [Abstract][Full Text] [Related]
15. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease].
Kuroda G
Nihon Naibunpi Gakkai Zasshi; 1987 Mar; 63(3):247-59. PubMed ID: 3111899
[TBL] [Abstract][Full Text] [Related]
16. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
[TBL] [Abstract][Full Text] [Related]
17. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
Saffan D; Seibel MM
Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a specific role of GnRH pulse frequency in the control of the human menstrual cycle.
Filicori M; Flamigni C; Campaniello E; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A; Valdiserri A
Am J Physiol; 1989 Dec; 257(6 Pt 1):E930-6. PubMed ID: 2514600
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
20. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
